Mike and I recently had the opportunity to regroup with Jody Vance on Equity Guru for a business update on a range of our current advancements.
There is extensive discussion about our work with Ivermectin – including our upcoming advanced BSL-4 lab COVID-19 clearance trial and its significant therapeutic implications globally. And we take a few minutes to run through our current work on cold chain, our dose sparing adjuvant, mucosal immunity and more.
You can watch our interview with Jody Vance here:
|